Business Context and Reporting Period
This Form 8-K was filed by Akebia Therapeutics, Inc. on April 2, 2020, reporting a material event that occurred on the same date. The company is a biopharmaceutical firm focused on developing treatments for kidney disease and other conditions.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual agreement rather than financial performance results.
Material Changes
The primary material change is the entry into a new Supply Agreement with STA Pharmaceutical Hong Kong Limited (a subsidiary of Wuxi AppTec, referred to as "WuXi STA"). This agreement establishes WuXi STA as a commercial manufacturer for the drug substance (API) of Akebia's Phase 3 product candidate, vadadustat. This action aligns with prior disclosures in the 2019 10-K regarding the intent to secure additional supply arrangements.
Agreement Terms and Outlook
- Term: The initial term is four years, running from April 2, 2020, to April 2, 2024, with the possibility of extension by mutual agreement.
- Pricing: The agreement utilizes a volume-based pricing structure.
- Forecasting: Akebia is obligated to provide rolling quarterly forecasts of API needs.
- Termination: Akebia retains the right to terminate the agreement for any reason with 180 days' prior written notice.
- Scope: The agreement covers customary terms including indemnification, intellectual property protection, confidentiality, and quality requirements.
The full text of the Supply Agreement is expected to be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ending June 30, 2020.
Investor Verification Checklist
- Verify the specific volume-based pricing tiers and cost implications in the full Supply Agreement exhibit.
- Confirm the status of vadadustat's Phase 3 clinical trials and regulatory approval timeline to assess the necessity of commercial manufacturing capacity.
- Review the company's cash position in the upcoming 10-Q to ensure sufficient liquidity to fund the new supply commitments.
- Monitor for any updates on the existing supply agreements with Esteve Quimica, S.A. and Patheon Inc. to understand the total manufacturing footprint.